Skip to main content
Erschienen in: Italian Journal of Pediatrics 1/2022

Open Access 01.12.2022 | Case report

Hypertrophic pyloric stenosis masked by kidney failure in a male infant with a contiguous gene deletion syndrome at Xp22.31 involving the steroid sulfatase gene: case report

verfasst von: Ingrid Anne Mandy Schierz, Mario Giuffrè, Marcello Cimador, Maria Michela D’Alessandro, Gregorio Serra, Federico Favata, Vincenzo Antona, Ettore Piro, Giovanni Corsello

Erschienen in: Italian Journal of Pediatrics | Ausgabe 1/2022

Abstract

Background

Contiguous gene deletion syndrome at Xp22.3 resulting in nullisomy in males or Turner syndrome patients typically encompasses the steroid sulfatase gene (STS) and contiguously located other genes expanding the phenotype. In large deletions, that encompass also the Kallmann syndrome 1 gene (KAL1), occasionally infantile hypertrophic pyloric stenosis (IHPS) and congenital anomalies of the kidney and urinary tract (CAKUT) have been reported.

Patient presentation

We report on a male newborn with family history in maternal uncle of renal abnormalities and short stature still without ichthyosiform dermatosis. The baby presented CAKUT with kidney failure and progressive vomiting. Renal bicarbonate loss masked hypochloremic and hypokalemic metabolic alkalosis classically present in IHPS and delayed its diagnosis. Antropyloric ultrasound examination and cystourethrography were diagnostic. After Fredet-Ramstedt extramucosal pyloromyotomy feeding and growing was regular and he was discharged home. Comparative whole-genome hybridization detected a maternal inherited interstitial deletion of 1.56 Mb on Xp22.31(6,552,712_8,115,153) × 0 involving the STS gene, but not the KAL1 gene.

Conclusions

Aberrant cholesterol sulfate storage due to STS deletion as the underlying pathomechanism is not limited to oculocutaneous phenotypes but could also lead to co-occurrence of both IHPS and kidney abnormalities, as we report. Thus, although these two latter pathologies have a high incidence in the neonatal age, their simultaneous association in our patient is resembling not a chance but a real correlation expanding the clinical spectrum associated with Xp22.31 deletions.
Hinweise

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Abkürzungen
ARSD
Arylsulfatase gene D
CAKUT
Congenital anomalies of the kidney and urinary tract
CAVIN1
Caveolae associated protein 1
DHCR7
7-dehydrocholesterol reductase
IHPS
Infantile hypertrophic pyloric stenosis
KAL1
Kallmann syndrome 1 gene
NOS
Nitric oxide synthase
OA1
Ocular albinism type I
PKD
Polycystic kidney disease
PNPLA4
Patatin like phospholipase domain containing-4
PUDP
Pseudouridine 5′-phospatase
SHOX
Short stature homeobox gene
STS
Steroid sulfatase gene
VCX
Variable charge X-linked

Background

Contiguous gene deletion syndrome at Xp22.3 resulting in nullisomy in males or Turner syndrome patients is characterized by the combination of one or more monogenic disorders and clinical findings as short stature (short stature homeobox gene, SHOX), chondrodysplasia punctata (arylsulfatase genes - ARSD, ARSE, ARSF), X-linked ichthyosis (arylsulfatase C or steroid sulfatase gene, STS), ocular albinism type I (OA1) and elements of X-linked neurodevelopmental disorders and Kallmann syndrome (KAL1; reduced hypothalamic and pituitary function with resulting hypogonadotropic hypogonadism and hypoplasia of the olfactory bulb) [1], whereas the term Rud’s syndrome should no longer be used [2]. FG syndrome 3 is also mapped to this region [3]. In large deletions, occasionally cardiac arrhythmia [4], periventricular nodular heterotopia [5], acute lymphoblastic leukemia [6], end-stage renal failure [7] and infantile hypertrophic pyloric stenosis (IHPS) [3, 4, 812] were also reported. The most critical region of deletion breakpoints, characterized by a low frequency of interspersed repeats and a low GC content [13], encompasses the STS gene (MIM*300747) resulting in microsomal enzyme deficiency with an incidence about 1:1500 in males [14]. This membrane-bound enzyme is ubiquitously expressed and hydrolyzes several 3-beta-hydroxysteroid sulfates, which serve as metabolic precursors for estrogens, androgens, and cholesterol [15]. Despite the widespread enzyme deficiency, patients apparently have abnormalities only of the stratum corneum where increased cholesterol sulphate concentrations are causing abnormal desquamation, decreased corneodesmosomal degradation and retention hyperkeratosis of the skin mostly a few weeks after birth, but conatal collodion is also reported [12]. There might be associated cardiac arrhythmia and benign Pre-Descemet corneal dystrophy characterized by cholesterol sulfate accumulation and punctiform opacities without vision impairment on the one side, as well as cryptorchidism and neurobehavioral disorders due to deficient (neuro-) steroids on the other side [4, 16]. Despite the escape of lyonization, some female deletion carriers also have corneal opacities and can present parturition disturbances and cervical dystocia due to lacking placental production of estriol [4, 14]. Congenital anomalies of the kidney and urinary tract (CAKUT) have been reported rarer in STS limited microdeletions or point mutations than in larger deletions of Xp22.3 that encompass also the KAL1 gene, a neighboring gene important for urogenital development [7, 12, 13, 17, 18].
We report on a male newborn with family history in maternal uncle of renal abnormalities and short stature still without ichthyosiform dermatosis. The baby presented CAKUT with kidney failure and progressive vomiting. Renal bicarbonate loss masked hypochloremic and hypokalemic metabolic alkalosis classically present in IHPS and delayed its diagnosis. This report of associated STS deletion and IHPS further define and expand the clinical spectrum associated with CNV in this region and provide support for the role of modifiers contributing to phenotypic variability.

Patient presentation

This male term newborn is the second son of healthy non consanguineous Caucasian parents. His maternal uncle suffering from nephropathy had undergone a kidney transplant. Fetal sonographic assessment revealed hydronephrosis bilaterally, and oligohydramnios inducted to Caesarean section. At birth baby’s weight was 2710 g (− 1.07 SDS/10th centile), length 46 cm (− 1.82 SDS/3rd centile), and head circumference 33 cm (− 1.09 SDS/14th centile). During the first week of life, he developed severe acidosis and was referred to our department. Physical examination was unremarkable except for pale skin and hyporeactive aspect; male genitals were normal. There were no edemas. Diuresis, and blood pressure were normal. Laboratory investigations diagnosed renal insufficiency by low bicarbonates 15 mmol/l, augmented creatininemia 3.12 mg/dl, urea 89 mg/dl, chlor 120 mEq/l, moderate proteinuria 327 mg/l, glucosuria 500 mg/l and microhematuria, while anion gap, albuminemia, proteinemia and uric acid were preserved. Abdominal ultrasound and subsequent voiding cystourethrography showed renal hypoplasia on the left and renal dysplasia on the right as well as moderate hydronephrosis due to grade IV vesicoureteral reflux. X-ray, cranial and cardiac ultrasounds and electrocardiogram were normal. He started intravenous rehydration and bicarbonate supplementation. Refeeding by breast milk and a special powdered feed with low levels of potassium for renal impairment (Kindergen® 1 g in 5 ml water) was initiated after 12 h. He tended to have regurgitations attributed to a urinary infection and treated on the fifth day of the hospital stay with oral amoxicillin switched to oral cefixime on day 14 (sensitive to Escherichia coli) until negative urinary cultures were reported. Persistent regurgitation did not ameliorate by trials of smaller, more frequent feeds, thickened formula, and anti-Trendelenburg positional management. At 1 month of age, intermittent nonbilious vomiting increased markedly, he weighed 3110 g (< 0.4 centile), creatininemia and urea were halved, bicarbonates kalium and chlor were normal.
Antropyloric ultrasound examination revealed hypertrophied muscular layer of 4.6 mm and elongation of the pyloric canal of 19 mm (diameter 14 mm). In retrospect, some frame of the cystourethrogram had already shown an air-filled stomach with undulating contours known as “Caterpillar sign” (Fig. 1). Fredet-Ramstedt extramucosal longitudinal pyloromyotomy was performed. Afterwards, feeding and growing was regular and he was discharged home 45 days old. All treatment options have been discussed with both parents. Erythropoietin treatment and clinical multidisciplinary follow-up are ongoing. At 6 month of age, large polygonal, brownish scales appeared particularly on the anterior aspect of the lower extremities.
Comparative whole-genome hybridization was performed during hospitalization using the Agilent® 8x60K microarray and detected a maternal inherited interstitial deletion of 1.56 Mb on arr [hg19] Xp22.31(6,552,712_8,115,153) × 0 involving the genes STS, variable charge X-linked (VCX; *300229), pseudouridine 5′-phospatase (PUDP; *306480), Patatin like phospholipase domain containing-4 (PNPLA4; *300102) and microRNA MIR4767 and MIR651.

Discussion and conclusion

We report on a male newborn with nonaccidental association of IHPS, kidney failure and maternal Xp22.3 deletion involving the STS gene.
IHPS is the most common form of gastrointestinal obstruction in infancy (1:700), five times more frequent in males than in females and hereditably is high as 87% [19, 20]. Isolated and syndromic IHPS are described [21]. The exact etiology of isolated IHPS is unknown, although neuronal nitric oxide synthase (NOS) upregulation and an extracellular matrix abnormality have been reported in subsets [21]. Various potential genetic loci have been investigated, as well as various environmental factors (maternal smoking or young age, firstborn, feeding practice, post-natal erythromycin use) without producing conclusive data. Interestingly, reducing erythromycin indications and increasing dietary intake of omega-3 fatty acids in Western countries during the last decade probably decreased the incidence of isolated IHPS [20, 22]. By studying syndromic IHPS (Table 1) it was evidenced that the lipid metabolism plays a fundamental role in etiopathogenesis [23]. The risk of IHPS is inversely and significantly associated with total cholesterol level with an Odds ratio of 0.77 (95% CI, 0.64–0.92; p = 0.005) per 10 mg/dL [24]. Indeed, there are higher incidence of IHPS in syndromes affecting the lipid metabolism. A classic example is the Smith-Lemli-Opitz syndrome, an autosomal recessive congenital disorder caused by mutations in the 7-dehydrocholesterol reductase (DHCR7) gene at 11q13. Affected individuals are unable to complete the final step in cholesterol biosynthesis with accumulation of aberrant 7-dehydrocholesterol in developing tissues causing a wide range of metabolic and developmental abnormalities, including IHPS in 10–15% of cases [21]. In congenital generalized lipodystrophy type IV (CAVIN1 gene at 17q21) diffuse skeletal and smooth muscle hypertrophy are leading to cardiac arrythmia and IHPS [21, 25]. In syndromes associated with hypotonia, as in FG syndrome 3 (Xp22.3) or Down syndrome (critical region 21q22.3), the IHPS incidence is about 7% [3, 21]. Other syndromes frequently associated with IHPS are connective tissue disorders in which abnormal or excess of connective tissue in the pylorus gradually develop mechanic obstruction [21]. Furthermore, biopsies have shown not only muscle layer hypertrophy but also accumulation of extracellular matrix molecules (chondroitin-sulfate proteoglycan and fibronectin) [26]. This is also the underlying cause for unsuccessful non-surgical conservative treatment with oral or intravenous administration of atropine, leaving the surgical extramucosal pyloromyotomy as the gold standard [27].
Table 1
Differential diagnosis of syndromic infantile hypertrophic pyloric stenosis (IHPS) and renal anomalies as variable features (Bioinformatics were obtained from open-source GeneCards.​org and MalaCards.​org and from Peeters et al. [21])
Cytogenetic region/gene(s)
n. of IHPS cases
Mode of inheritance
Phenotype
1p36/SKI, SPEN, RERE, PRDM16, GABRD, HSPG2
1–4
 
1p36 deletion syndrome (craniofacial dysmorphism, hydrocephalus, genitourinary and neurodevelopmental disorders)
2q22.3/ZEB2
1–4
AD
Mowat-Wilson syndrome (craniofacial dysmorphism, deep set eyes, Hirschsprung disease, hydronephrosis)
2q37.3/HDAC4
1–4
AD
2q37 microdeletion syndrome (round face, multicystic kidneys, neurodevelopmental disorders)
3p25
1–4
AD
3p25 microdeletion syndrome (trigonocephaly, microcephaly, cardiac and genitourinary malformations, neurodevelopmental disorders); Noonan syndrome 5 (3p25.2/RAF1 mutations)
4q22.1/PKD2
1–4
AD
Polycystic kidney disease 2, laterality defects
5p13.2/NIPBL
11–50
AD
Cornelia de Lange syndrome (microbrachicephaly, synorphrys, growth retardation, genitourinary malformations, cardiac and neurodevelopmental disorders)
6p12.3-p12.2/PKHD1
1–4
AR
Polycystic kidney disease 4, Caroli disease
6p24.3/TFAP2A
1–4
AD
Branchiooculofacial syndrome (orofacial clefts, hearing loss, renal agenesis or cystic anomalies)
6q15/MAP 3 K7
1–4
AD
Frontometaphyseal dysplasia 2, cardiac and genitourinary malformations
7q21.2/PEX1
1–4
AR
Zellweger syndrome (extreme hypotonia, seizures, renal and hepatic cysts/dysfunction)
8q12.2/CHD7
1–4
AD
CHARGE syndrome (coloboma, heart anomaly, choanal atresia, genitourinary and ear malformations); Kallmann syndrome (anosmia, hypogonadotropic hypogonadism)
10q24.32/NFKB2
1–4
AD
Common variable immunodeficiency-10, nephrotic syndrome
10q26/FGFR2
1–4
AD
Apert syndrome (craniosynostosis, complete syndactyly, hydronephrosis); Beare-Stevenson syndrome (craniosynostosis, cutis gyrate)
11p13/WT1
1–4
AD
Denys-Drash syndrome (genitourinary malformations and neoplasia)
11p15.5/HRAS
5–10
AD
Costello syndrome (fetal overgrowth, craniofacial dysmorphism, periorificial papillomata, echogenic kidneys, cardiomyopathy, neurodevelopmental disorders)
11q13.4/DHCR7
11–50
AR
Smith-Lemli-Opitz syndrome (short stature, craniofacial dysmorphism, cleft palate, genitourinary malformations, syndactyly of second and third toes, cardiac and neurodevelopmental disorders)
12q23.2/PAH
5–10
AR
Phenylketonuria (microcephaly, pale pigmentation, neurodevelopmental disorders if not recognized)
12q24.11/UBE3B
1–4
AR
Kaufman oculocerebrofacial syndrome (facial dysmorphism, cardiac, genitourinary malformations and neurodevelopmental disorders)
12q24.13/PTPN11
1–4
AD
Noonan syndrome 1 (short stature, facial dysmorphism, wolly hair, webbed neck, cardiac and genitourinary malformations)
Trisomy 13
1–4
 
Patau syndrome (hypotelorism, orofacial clefts, polydactyly, aplasia cutis, visceral malformations)
14q13.2/PPP2R3C
1–4
AR
Gonadal dysgenesis, dysmorphic facies, retinal dystrophy, myopathy
14q32
1–4
AD
Temple syndrome (short stature, maternal disomy)
16p13.3
1–4
AD
Polycystic kidney disease 1, intracranial aneurysm
16q22.2/DHODH
1–4
AR
Miller syndrome (postaxial acrofacial dysostosis, genitourinary malformations)
17q12/HNF1B
1–4
AD
HNF1B-related tubulointerstitial kidney disease, diabetes
17q21/CAVIN1
5–10
AR
Congenital generalized lipodystrophy type IV (muscular dystrophy, arrhythmia, phlebomegaly)
17q21.31/KANSL1
1–4
AD
Koolen-De Vries syndrome (craniofacial dysmorphism, cardiac and genitourinary malformations)
Trisomy 18 (18p)
5–10
 
Edwards’ syndrome (craniofacial dysmorphism, omphalocele, verticaltalus, visceral malformations)
18p11/PIEZO2
1–4
AD
Marden-Walker syndrome (microcephaly, blepharophimosis, arthrogryposis, genitourinary malformations)
18q21.32/CCBE1
1–4
AR
Hennekam lymphangiectasia-lymphedema syndrome
19q13.12/NPHS1
5–10
AR
Nephrotic syndrome type 1, hyperlipidemia
19p13.2/ZNF699
1–4
AR
DEGCAGS syndrome (neurodevelopmental disorders, visceral malformations)
19q13.2/LTBP4
1–4
AR
Cutis laxa type Ic (hydronephrosis, bladder diverticula)
20q13.33/SOX18
1–4
AD
Glomerulonephritis, hypotrichosis, lymphedema, telangiectasia
Trisomy 21
> 50
 
Down syndrome (hypotonia, craniofacial dysmorphism, sandal gap, cardiac and gastrointestinal malformations, neurodevelopmental disorders)
21q22.3/COL18A1
1–4
AR
Knobloch syndrome (eye and CNS abnormalities, aplasia cutis, duplex kidneys or ureters)
22q11.2/BCR, MAPK1
1–4
 
22q11.2 microdeletion syndrome
Xp11/SMC1A
11–50
XL
Cornelia de Lange syndrome (microbrachicephaly, synorphrys, genitourinary malformations, neurodevelopmental disorders)
Xp11.4/BCOR
1–4
XL
Lenz microphthalmia, genitourinary malformations
Xp22/STS, FGS3, KAL1
5–10
XL
X-linked ichthyosis; FG syndrome (hypotonia, macrocephaly, craniofacial dysmorphism, anorectal malformations); Kallmann syndrome (anosmia, hypogonadotropic hypogonadism)
Xq11.2/AMER1
1–4
XL
Osteopathia striata, macrocephaly, cranial sclerosis, multicystic kidneys, male lethality
Xq13/MED12
5–10
XL
FG syndrome type 1 also known as Opitz-Kaveggia (hypotonia, macrocephaly, anorectal malformation)
Xq26.2/GPC3
1–4
XL
Overgrowth, organomegaly
Xq28/FLNA, NAA10
1–4
XL
Pseudoobstruction, hydronephrosis, aortic valvular dysplasia; Lenz microphthalmia; frontometaphyseal dysplasia
Abbreviations: AD Autosomal dominant, AMER1 APC membrane recruitment protein 1, AR Autosomal recessive, BCOR corepressor for B-cell lymphoma 6, BCR Breakpoint cluster region, CAVIN1 Caveolae associated protein 1, CCBE1 Collagen and calcium-binding EGF domains 1, CHD7 Chromodomain helicase DNA binding protein 7, CNS Central nervous system, COL18A1 Collagen type XVIII alpha 1 chain, DHCR7 7-dehydrocholesterol reductase gene, DHODH Dihydroorotate dehydrogenase gene, PKHD1 ciliary IPT domain containing fibrocystin/polyductin, FGFR2 fibroblast growth factor receptor 2, FGS3 FG syndrome 3, FLNA Filamin A, GABRD Gamma-aminobutyric acid type A receptor subunit delta, GPC3 Glypican 3, HDAC4 Histone deacetylase 4, HNF1B Hepatocyte nuclear factor-1-beta, HRAS HRas Proto-Oncogene, HSPG2 Heparan sulfate proteoglycan 2, KAL1 anosmin 1, KANSL1 KAT8 regulatory NSL complex subunit 1, LTBP4 Latent transforming growth factor beta binding protein 4, MAP 3 K7 Mitogen-activated protein kinase kinase kinase 7, MAPK1 Mitogen-activated protein kinase 1, MED12 Mediator complex subunit 12, NAA10 N-alpha-acetyltransferase 10 NatA catalytic subunit, NFKB2 Nuclear factor kappa B subunit 2, NIPBL Nipped-B-like, NPHS1 Nephrin, PAH Phenylalanine hydroxylase, PEX1 Peroxisomal biogenesis factor 1, PIEZO2 Piezo type mechanosensitive ion channel component 2, PKD2 Polycystin, PPP2R3C Protein phosphatase 2 regulatory subunit B-double prime gamma, PRDM16 PR/SET domain 16, PTPN11 Protein tyrosine phosphatase non-receptor type 11, RAF1 Raf-1 proto-oncogene, RERE Arginine-glutamic acid dipeptide repeats, SKI SKI proto-oncogene, SMC1A Structural maintenance of chromosomes 1A, SOX18 SRY-box transcription factor 18, SPEN Spen family transcriptional repressor, STS Steroid sulfatase, TFAP2A transcription factor AP-2 alpha, UBE3B Ubiquitin protein ligase E3B, WT1 Wilms tumor 1 transcription factor, XL X-linked, ZEB2 Zinc finger E-box binding homeobox 2, ZNF699 Zinc finger protein 699
STS alterations as in our case report, can lead to disturbed intracellular metabolism of cholesterol and to storage phenomenon of cholesterol sulphate. It was evidenced that age of onset of ichthyosis or absent/mild forms of XLI, frequently found in Southern European countries, are not related to width of Xp22.3 deletion [12, 18]. The late-onset of cutaneous presentation in our newborn is possible and clinical follow up have to direct dermatological, nephrological, endocrinological and neurobehavioral care as well as infection surveillance. VCX, PUDP and mitochondria-related PNPLA4 have been implicated in neurocognitive development, although the functional significance of these genes remains under debate [11, 13]. KAL1 gene, implicated in urogenital development, is not deleted in our case.
Vomiting and growth failure present a clinical challenge in neonatal age. Major causes are severe gastroesophageal reflux, neonatal sepsis, anatomical and functional gastrointestinal obstructions including IHPS and pylorospasm; less frequent are food allergy, inborn errors of metabolism, congenital adrenal hyperplasia, intracerebral abnormalities such as subdural hemorrhage or hydrocephalus, drugs or toxic agents and/or renal tubular acidosis. This spectrum widens in case of CAKUT, as in our patient, including renal impairment, risk of urosepsis and renal adapted diet. A concomitant edema could involve also the antropyloric region and cases of IHPS have been described [28]. Interestingly, a frequent recurrence linked polycystic kidney disease (PKD) and IHPS to NOS deficiency [29, 30]. Renal neuronal NOS and inducible NOS in cystic epithelium are suppressed or lost in PKD rats [31]. Thus, NOS deficiency leads to lack of locally available nitric oxide which may cause pyloric stenosis as a result of failure of smooth muscle relaxation. Downregulation of nitric oxide production may also be involved in the pathogenesis of pyloric stenosis in this subset. On the other hand, it was shown that deficiency of STS in kidneys results in increased cholesterol sulfate accumulation which interferes with normal functioning of transglutaminase 1, responsible for maintaining the integrity of cadherin-based adherens junctions between epithelial cells. The slit diaphragm of glomerular visceral epithelial cells is a modified adherens junction and, therefore, disruption of its structure by the above mechanism can result in proteinuria [7].
In conclusion, aberrant cholesterol sulfate storage due to STS deletion as the underlying pathomechanism is not limited to oculocutaneous phenotypes but could also lead to co-occurrence of both IHPS and kidney abnormalities, as we report. Thus, although these two latter pathologies have a high incidence in the neonatal age, their simultaneous association in our patient is resembling not a chance but a real correlation expanding the clinical spectrum associated with Xp22.31 deletions.

Acknowledgements

Not applicable.

Declarations

Parent’s informed written consent was provided.
Not applicable.

Competing interests

Not applicable.
Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://​creativecommons.​org/​licenses/​by/​4.​0/​. The Creative Commons Public Domain Dedication waiver (http://​creativecommons.​org/​publicdomain/​zero/​1.​0/​) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Literatur
1.
Zurück zum Zitat Davies W. The contribution of Xp22.31 gene dosage to turner and Klinefelter syndromes and sex-biased phenotypes. Eur J Med Genet. 2021;64(4):104169.CrossRef Davies W. The contribution of Xp22.31 gene dosage to turner and Klinefelter syndromes and sex-biased phenotypes. Eur J Med Genet. 2021;64(4):104169.CrossRef
2.
3.
Zurück zum Zitat Dessay S, Moizard MP, Gilardi JL, Opitz JM, Middleton-Price H, Pembrey M, et al. FG syndrome: linkage analysis in two families supporting a new gene localization at Xp22.3 [FGS3]. Am J Med Genet. 2002;112(1):6–11.CrossRef Dessay S, Moizard MP, Gilardi JL, Opitz JM, Middleton-Price H, Pembrey M, et al. FG syndrome: linkage analysis in two families supporting a new gene localization at Xp22.3 [FGS3]. Am J Med Genet. 2002;112(1):6–11.CrossRef
4.
Zurück zum Zitat Brcic L, Underwood JF, Kendall KM, Caseras X, Kirov G, Davies W. Medical and neurobehavioural phenotypes in carriers of X-linked ichthyosis-associated genetic deletions in the UK biobank. J Med Genet. 2020;57(10):692–8.CrossRef Brcic L, Underwood JF, Kendall KM, Caseras X, Kirov G, Davies W. Medical and neurobehavioural phenotypes in carriers of X-linked ichthyosis-associated genetic deletions in the UK biobank. J Med Genet. 2020;57(10):692–8.CrossRef
5.
Zurück zum Zitat Ozawa H, Osawa M, Nagai T, Sakura N. Steroid sulfatase deficiency with bilateral periventricular nodular heterotopia. Pediatr Neurol. 2006;34(3):239–41.CrossRef Ozawa H, Osawa M, Nagai T, Sakura N. Steroid sulfatase deficiency with bilateral periventricular nodular heterotopia. Pediatr Neurol. 2006;34(3):239–41.CrossRef
6.
Zurück zum Zitat Mallory SB, Kletzel M, Turley CP. X-linked ichthyosis with acute lymphoblastic leukemia. Arch Dermatol. 1988;124(1):22–4.CrossRef Mallory SB, Kletzel M, Turley CP. X-linked ichthyosis with acute lymphoblastic leukemia. Arch Dermatol. 1988;124(1):22–4.CrossRef
7.
Zurück zum Zitat Matsukura H, Fuchizawa T, Ohtsuki A, Higashiyama H, Higuchi O, Higuchi A, et al. End stage renal failure in a child with X- linked ichthyosis. Pediatr Nephrol. 2003;18:297–300.CrossRef Matsukura H, Fuchizawa T, Ohtsuki A, Higashiyama H, Higuchi O, Higuchi A, et al. End stage renal failure in a child with X- linked ichthyosis. Pediatr Nephrol. 2003;18:297–300.CrossRef
8.
Zurück zum Zitat Garcia Perez A, Crespo M. X-linked ichthyosis associated with hypertrophic pyloric stenosis in three brothers. Clin Exp Dermatol. 1981;6(2):159–61.CrossRef Garcia Perez A, Crespo M. X-linked ichthyosis associated with hypertrophic pyloric stenosis in three brothers. Clin Exp Dermatol. 1981;6(2):159–61.CrossRef
9.
Zurück zum Zitat Weissörtel R, Strom TM, Dörr HG, Rauch A, Meitinger T. Analysis of an interstitial deletion in a patient with Kallmann syndrome, X-linked ichthyosis and mental retardation. Clin Genet. 1998;54(1):45–51.CrossRef Weissörtel R, Strom TM, Dörr HG, Rauch A, Meitinger T. Analysis of an interstitial deletion in a patient with Kallmann syndrome, X-linked ichthyosis and mental retardation. Clin Genet. 1998;54(1):45–51.CrossRef
10.
Zurück zum Zitat Bruno L, Bocanegra O, Magnelli N. Recessive X-linked ichthyosis associated with hypertrophic pyloric stenosis: a chance occurrence? Clin Exp Dermatol. 2003;28(1):74–6.CrossRef Bruno L, Bocanegra O, Magnelli N. Recessive X-linked ichthyosis associated with hypertrophic pyloric stenosis: a chance occurrence? Clin Exp Dermatol. 2003;28(1):74–6.CrossRef
11.
Zurück zum Zitat Puri PK, Reddi DM, Spencer-Manzon M, Deak K, Steele SU, Mikati MA. Banding pattern on polarized hair microscopic examination and unilateral polymicrogyria in a patient with steroid sulfatase deficiency. Arch Dermatol. 2012;148(1):73–8.CrossRef Puri PK, Reddi DM, Spencer-Manzon M, Deak K, Steele SU, Mikati MA. Banding pattern on polarized hair microscopic examination and unilateral polymicrogyria in a patient with steroid sulfatase deficiency. Arch Dermatol. 2012;148(1):73–8.CrossRef
12.
Zurück zum Zitat Diociaiuti A, Angioni A, Pisaneschi E, Alesi V, Zambruno G, Novelli A, et al. X-linked ichthyosis: clinical and molecular findings in 35 Italian patients. Exp Dermatol. 2019;28(10):1156–63.CrossRef Diociaiuti A, Angioni A, Pisaneschi E, Alesi V, Zambruno G, Novelli A, et al. X-linked ichthyosis: clinical and molecular findings in 35 Italian patients. Exp Dermatol. 2019;28(10):1156–63.CrossRef
13.
Zurück zum Zitat Nagai K, Shima H, Kamimura M, Kanno J, Suzuki E, Ishiguro A, et al. Xp22.31 microdeletion due to microhomology-mediated break-induced replication in a boy with contiguous gene deletion syndrome. Cytogenet Genome Res. 2017;151(1):1–4.CrossRef Nagai K, Shima H, Kamimura M, Kanno J, Suzuki E, Ishiguro A, et al. Xp22.31 microdeletion due to microhomology-mediated break-induced replication in a boy with contiguous gene deletion syndrome. Cytogenet Genome Res. 2017;151(1):1–4.CrossRef
14.
Zurück zum Zitat Craig WY, Roberson M, Palomaki GE, Shackleton CH, Marcos J, Haddow JE. Prevalence of steroid sulfatase deficiency in California according to race and ethnicity. Prenat Diagn. 2010;30(9):893–8.CrossRef Craig WY, Roberson M, Palomaki GE, Shackleton CH, Marcos J, Haddow JE. Prevalence of steroid sulfatase deficiency in California according to race and ethnicity. Prenat Diagn. 2010;30(9):893–8.CrossRef
15.
Zurück zum Zitat Mueller JW, Gilligan LC, Idkowiak J, Arlt W, Foster PA. The regulation of steroid action by Sulfation and Desulfation. Endocr Rev. 2015;36(5):526–63.CrossRef Mueller JW, Gilligan LC, Idkowiak J, Arlt W, Foster PA. The regulation of steroid action by Sulfation and Desulfation. Endocr Rev. 2015;36(5):526–63.CrossRef
16.
Zurück zum Zitat Rudolf M, Grösch S, Geerling G. Rezidivierende bilaterale Erosio corneae und Trübungen im Hornhautstroma. Predescemet-Dystrophie bei X-chromosomaler rezessiver ichthyosis [recurrent bilateral corneal erosions and opacities in corneal stroma. Pre-Descemet dystrophy in X chromosome recessive ichthyosis]. Ophthalmologe. 2002;99(12):962–3.CrossRef Rudolf M, Grösch S, Geerling G. Rezidivierende bilaterale Erosio corneae und Trübungen im Hornhautstroma. Predescemet-Dystrophie bei X-chromosomaler rezessiver ichthyosis [recurrent bilateral corneal erosions and opacities in corneal stroma. Pre-Descemet dystrophy in X chromosome recessive ichthyosis]. Ophthalmologe. 2002;99(12):962–3.CrossRef
17.
Zurück zum Zitat Martul P, Pineda J, Levilliers J, Vazquez JA, Rodriguez-Soriano J, Loridan L, et al. Hypogonadotrophic hypogonadism with hyposmia, X-linked ichthyosis, and renal malformation syndrome. Clin Endocrinol. 1995;42(2):121–8.CrossRef Martul P, Pineda J, Levilliers J, Vazquez JA, Rodriguez-Soriano J, Loridan L, et al. Hypogonadotrophic hypogonadism with hyposmia, X-linked ichthyosis, and renal malformation syndrome. Clin Endocrinol. 1995;42(2):121–8.CrossRef
18.
Zurück zum Zitat Georgopoulos NA, Koika V, Galli-Tsinopoulou A, Spiliotis BE, Adonakis G, Keramida MK, et al. Renal dysgenesis and KAL1 gene defects in patients with sporadic Kallmann syndrome. Fertil Steril. 2007;88(5):1311–7.CrossRef Georgopoulos NA, Koika V, Galli-Tsinopoulou A, Spiliotis BE, Adonakis G, Keramida MK, et al. Renal dysgenesis and KAL1 gene defects in patients with sporadic Kallmann syndrome. Fertil Steril. 2007;88(5):1311–7.CrossRef
19.
Zurück zum Zitat Krogh C, Fischer TK, Skotte L, Biggar RJ, Øyen N, Skytthe A, et al. Familial aggregation and heritability of pyloric stenosis. JAMA. 2010;303(23):2393–9.CrossRef Krogh C, Fischer TK, Skotte L, Biggar RJ, Øyen N, Skytthe A, et al. Familial aggregation and heritability of pyloric stenosis. JAMA. 2010;303(23):2393–9.CrossRef
20.
Zurück zum Zitat Oetzmann von Sochaczewski C, Muensterer OJ. The incidence of infantile hypertrophic pyloric stenosis nearly halved from 2005 to 2017: analysis of German administrative data. Pediatr Surg Int. 2021;37(5):579–85.CrossRef Oetzmann von Sochaczewski C, Muensterer OJ. The incidence of infantile hypertrophic pyloric stenosis nearly halved from 2005 to 2017: analysis of German administrative data. Pediatr Surg Int. 2021;37(5):579–85.CrossRef
21.
Zurück zum Zitat Peeters B, Benninga MA, Hennekam RC. Infantile hypertrophic pyloric stenosis--genetics and syndromes. Nat Rev Gastroenterol Hepatol. 2012;9:646–60.CrossRef Peeters B, Benninga MA, Hennekam RC. Infantile hypertrophic pyloric stenosis--genetics and syndromes. Nat Rev Gastroenterol Hepatol. 2012;9:646–60.CrossRef
22.
Zurück zum Zitat Paran M, Freud E, Samuk I, Steiner Z. Does maternal omega 3 supplementation protect against infantile hypertrophic pyloric stenosis? J Pediatr Gastroenterol Nutr. 2020;70(5):652–6.CrossRef Paran M, Freud E, Samuk I, Steiner Z. Does maternal omega 3 supplementation protect against infantile hypertrophic pyloric stenosis? J Pediatr Gastroenterol Nutr. 2020;70(5):652–6.CrossRef
23.
Zurück zum Zitat Chung E. Infantile hypertrophic pyloric stenosis: genes and environment. Arch Dis Child. 2008;93:1003–4.CrossRef Chung E. Infantile hypertrophic pyloric stenosis: genes and environment. Arch Dis Child. 2008;93:1003–4.CrossRef
24.
Zurück zum Zitat Feenstra B, Geller F, Carstensen L, Romitti PA, Körberg IB, Bedell B, et al. Plasma lipids, genetic variants near APOA1, and the risk of infantile hypertrophic pyloric stenosis. JAMA. 2013;310(7):714–21.CrossRef Feenstra B, Geller F, Carstensen L, Romitti PA, Körberg IB, Bedell B, et al. Plasma lipids, genetic variants near APOA1, and the risk of infantile hypertrophic pyloric stenosis. JAMA. 2013;310(7):714–21.CrossRef
25.
Zurück zum Zitat Rajab A, Straub V, McCann LJ, Seelow D, Varon R, Barresi R, et al. Fatal cardiac arrhythmia and long-QT syndrome in a new form of congenital generalized lipodystrophy with muscle rippling (CGL4) due to PTRF-CAVIN mutations. Plos Genet. 2010;6(3):e1000874.CrossRef Rajab A, Straub V, McCann LJ, Seelow D, Varon R, Barresi R, et al. Fatal cardiac arrhythmia and long-QT syndrome in a new form of congenital generalized lipodystrophy with muscle rippling (CGL4) due to PTRF-CAVIN mutations. Plos Genet. 2010;6(3):e1000874.CrossRef
26.
Zurück zum Zitat Pueyo Gil C, Oshiro K, Elías Pollina J, Esteban Ibarz JA, Puri P. Aumento de la expresión del proteoglicano condroitín-sulfato, fibronectina y fibroblastos en la estenosis hipertrófica de píloro [Increase of the chondroitin-sulfate proteoglycan, fibronectin and fibroblasts in infantile hypertrophic pyloric stenosis]. Cir Pediatr. 2001;14(3):103–7.PubMed Pueyo Gil C, Oshiro K, Elías Pollina J, Esteban Ibarz JA, Puri P. Aumento de la expresión del proteoglicano condroitín-sulfato, fibronectina y fibroblastos en la estenosis hipertrófica de píloro [Increase of the chondroitin-sulfate proteoglycan, fibronectin and fibroblasts in infantile hypertrophic pyloric stenosis]. Cir Pediatr. 2001;14(3):103–7.PubMed
27.
Zurück zum Zitat Chiarenza SF, Bleve C, Escolino M, Esposito C, Beretta F, Cheli M, Scuderi MG, Di Benedetto V, Casadio G, Marzaro M, Gambino M, Conforti A, Pini Prato A, Molinaro F, Gerocarni Nappo S, Caione P, Mendoza-Sagaon M. Guidelines of the Italian Society of Videosurgery (SIVI) in infancy for the minimally invasive treatment of hypertrophic pyloric stenosis in neonates and infants. Pediatr Med Chir. 2020;42(1):16–24. https://doi.org/10.4081/pmc.2020.243. Chiarenza SF, Bleve C, Escolino M, Esposito C, Beretta F, Cheli M, Scuderi MG, Di Benedetto V, Casadio G, Marzaro M, Gambino M, Conforti A, Pini Prato A, Molinaro F, Gerocarni Nappo S, Caione P, Mendoza-Sagaon M. Guidelines of the Italian Society of Videosurgery (SIVI) in infancy for the minimally invasive treatment of hypertrophic pyloric stenosis in neonates and infants. Pediatr Med Chir. 2020;42(1):16–24. https://​doi.​org/​10.​4081/​pmc.​2020.​243.
28.
Zurück zum Zitat Takahashi T, Sato Y, Yamazaki T, Hayashi A, Okamoto T. Vomiting in an infant with congenital nephrotic syndrome: questions. Pediatr Nephrol. 2017;32(9):1519–20.CrossRef Takahashi T, Sato Y, Yamazaki T, Hayashi A, Okamoto T. Vomiting in an infant with congenital nephrotic syndrome: questions. Pediatr Nephrol. 2017;32(9):1519–20.CrossRef
29.
Zurück zum Zitat Tennakoon J, Koh TH, Alcock G. Pyloric stenosis in a newborn baby with polycystic kidneys. J Perinatol. 2007;27(2):125–6.CrossRef Tennakoon J, Koh TH, Alcock G. Pyloric stenosis in a newborn baby with polycystic kidneys. J Perinatol. 2007;27(2):125–6.CrossRef
30.
Zurück zum Zitat Mishra K, Batra VV, Basu S, Rath B, Saxena R. Steroid-resistant nephrotic syndrome associated with steroid sulfatase deficiency-x-linked recessive ichthyosis: a case report and review of literature. Eur J Pediatr. 2012;171(5):847–50.CrossRef Mishra K, Batra VV, Basu S, Rath B, Saxena R. Steroid-resistant nephrotic syndrome associated with steroid sulfatase deficiency-x-linked recessive ichthyosis: a case report and review of literature. Eur J Pediatr. 2012;171(5):847–50.CrossRef
31.
Zurück zum Zitat Wang D, Braendstrup OB, Larsen S, Horn T, Strandgaard S. The expression and activity of renal nitric oxide synthase and circulating nitric oxide in polycystic kidney disease rats. APMIS. 2004;112:358–68.CrossRef Wang D, Braendstrup OB, Larsen S, Horn T, Strandgaard S. The expression and activity of renal nitric oxide synthase and circulating nitric oxide in polycystic kidney disease rats. APMIS. 2004;112:358–68.CrossRef
Metadaten
Titel
Hypertrophic pyloric stenosis masked by kidney failure in a male infant with a contiguous gene deletion syndrome at Xp22.31 involving the steroid sulfatase gene: case report
verfasst von
Ingrid Anne Mandy Schierz
Mario Giuffrè
Marcello Cimador
Maria Michela D’Alessandro
Gregorio Serra
Federico Favata
Vincenzo Antona
Ettore Piro
Giovanni Corsello
Publikationsdatum
01.12.2022
Verlag
BioMed Central
Erschienen in
Italian Journal of Pediatrics / Ausgabe 1/2022
Elektronische ISSN: 1824-7288
DOI
https://doi.org/10.1186/s13052-022-01218-5

Weitere Artikel der Ausgabe 1/2022

Italian Journal of Pediatrics 1/2022 Zur Ausgabe

ADHS-Medikation erhöht das kardiovaskuläre Risiko

16.05.2024 Herzinsuffizienz Nachrichten

Erwachsene, die Medikamente gegen das Aufmerksamkeitsdefizit-Hyperaktivitätssyndrom einnehmen, laufen offenbar erhöhte Gefahr, an Herzschwäche zu erkranken oder einen Schlaganfall zu erleiden. Es scheint eine Dosis-Wirkungs-Beziehung zu bestehen.

Erstmanifestation eines Diabetes-Typ-1 bei Kindern: Ein Notfall!

16.05.2024 DDG-Jahrestagung 2024 Kongressbericht

Manifestiert sich ein Typ-1-Diabetes bei Kindern, ist das ein Notfall – ebenso wie eine diabetische Ketoazidose. Die Grundsäulen der Therapie bestehen aus Rehydratation, Insulin und Kaliumgabe. Insulin ist das Medikament der Wahl zur Behandlung der Ketoazidose.

Frühe Hypertonie erhöht späteres kardiovaskuläres Risiko

Wie wichtig es ist, pädiatrische Patienten auf Bluthochdruck zu screenen, zeigt eine kanadische Studie: Hypertone Druckwerte in Kindheit und Jugend steigern das Risiko für spätere kardiovaskuläre Komplikationen.

Betalaktam-Allergie: praxisnahes Vorgehen beim Delabeling

16.05.2024 Pädiatrische Allergologie Nachrichten

Die große Mehrheit der vermeintlichen Penicillinallergien sind keine. Da das „Etikett“ Betalaktam-Allergie oft schon in der Kindheit erworben wird, kann ein frühzeitiges Delabeling lebenslange Vorteile bringen. Ein Team von Pädiaterinnen und Pädiatern aus Kanada stellt vor, wie sie dabei vorgehen.

Update Pädiatrie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.